Poor survival in prostate cancer patients with primary refractoriness to docetaxel

摘要

In the last few years, the therapeutic armamentarium for castration-resistant prostate cancer (CRPC) has expanded to include an impressive number of agents including abir-aterone, enzalutamide, cabazitaxel, radium-223, and sipu-leucel-T [1-3]. In patients failing docetaxel, the best timing and sequence of use of the multiple available agents have not been assessed in randomized controlled trials, although the number of predictive/prognostic factors of potential interest to guide treatment selection is growing [1,4]. The